Filing Flows › Cytek Biosciences (CTKB) › Q1 2026
Cytek Biosciences (CTKB) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Cytek Biosciences (CTKB) reported revenue of $44.1M for the first quarter 2026 (Q1 2026), +6% from a year earlier and -29% from the quarter before. Operating margin was -41.8%, net loss $18.9M (42.7% of revenue).
Cytek Biosciences, Q1 2026: revenue $44.1M (+6% year over year), operating margin -41.8%, net loss $18.9M, operating cash flow −$2.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $44.1M | -29% | +6% |
| Operating profit | −$18.5M | — | — |
| Net earnings | −$18.9M | — | — |
| Operating cash flow | −$2.7M | — | — |
What changed
Revenue was $44.1M in Q1 2026, up 6% year over year and down 29% from the previous quarter. Product was the largest line at 65% of revenue. Service added $2.0M year over year (up 15%), 75% of the total change.
Gross margin was 48.2%, down 0.5 points from Q1 2025. Operating costs exceeded revenue by $18.5M, an operating margin of -41.8%. Operating expenses grew 13% against revenue growth of 6%. The fastest-growing cost line was General & admin (+43%). The quarter ended with a net loss of $18.9M, narrower than the previous quarter's $44.1M loss.
Operating cash flow was −$2.7M. Non-cash charges added back $1.9M of depreciation and amortization and $4.9M of share-based compensation. Working capital and other items added $9.4M. Capital expenditures of $2.2M exceeded it, leaving free cash flow of −$4.9M.
Questions
What was Cytek Biosciences' revenue in the first quarter 2026?
Cytek Biosciences (CTKB) reported revenue of $44.1M for the first quarter 2026 (Q1 2026), +6% from a year earlier and -29% from the quarter before.
Was Cytek Biosciences profitable in the first quarter 2026?
Operating loss was $18.5M (-41.8% of revenue) and net loss $18.9M.
Source: Cytek Biosciences 10-Q on SEC EDGAR.